Items where authors include "Fleischmann, R"

Export as [feed] Atom [feed] RSS
Number of items: 10.

Article

Conaghan, P orcid.org/0000-0002-3478-5665, Cohen, S, Burmester, G et al. (11 more authors) (2021) Benefit-Risk Analysis of Upadacitinib compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy. ISSN 2198-6576 (In Press)

Fautrel, B, Zhu, B, Taylor, PC et al. (8 more authors) (2020) Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open, 6. e001131. ISSN 2056-5933

Taylor, PC, Lee, YC, Fleischmann, R et al. (12 more authors) (2019) Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. Journal of Clinical Medicine, 8 (6). 831. ISSN 2077-0383

Aaboud, M, Aad, G, Abbott, B et al. (2847 more authors) (2018) Measurement of the production cross section of three isolated photons in pp collisions at root s=8 TeV using the ATLAS detector. Physics Letters B, 781. pp. 55-76. ISSN 0370-2693

Aaboud, M, Aad, G, Abbott, B et al. (2880 more authors) (2018) A search for resonances decaying into a Higgs boson and a new particle X in the XH -> qqbb final state with the ATLAS detector. Physics Letters B, 779. pp. 24-45. ISSN 0370-2693

Kavanaugh, A, van Vollenhoven, RF, Fleischmann, R et al. (7 more authors) (2018) Testing Treat-to-Target Outcomes With Initial Methotrexate Monotherapy Compared With Initial Tumor Necrosis Factor Inhibitor (Adalimumab) Plus Methotrexate in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 77 (2). pp. 289-292. ISSN 0003-4967

Weinblatt, ME, Fleischmann, R, van Vollenhoven, RF et al. (8 more authors) (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 17. 325. ISSN 1478-6354

Conference or Workshop Item

Helliwell, P, Lespessailles, E, Shuler, CL et al. (4 more authors) (2018) Ixekizumab Provides Sustained Improvement In Signs And Symptoms In Patients With Active Psoriatic Arthritis: Two Year Results From A Phase 3 Trial. In: 20th PANLAR Meeting, 07-10 Apr 2018, Buenos Aires, Argentina.

Proceedings Paper

Helliwell, P, Lespessailles, E, Shuler, C et al. (4 more authors) (2018) Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two-Year Results from a Phase 3 Trial. In: Journal of Rheumatology. 73rd Annual Meeting of The Canadian-Rheumatology-Association (CRA), 21-24 Feb 2018, Vancouver, Canada. Journal of Rheumatology Publishing Co., Ltd. , pp. 998-999.

Chandran, V, Fleischmann, R, Lespessailles, E et al. (4 more authors) (2018) Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1). In: Acta Dermato-Venereologica. 5th World Psoriasis & Psoriatic Arthritis Conference, 27-30 Jun 2018, Stockholm, Sweden. Society for Publication of Acta Dermato-Venereologica , pp. 23-24.

This list was generated on Sat Nov 26 12:09:26 2022 GMT.